Compare ARKO & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | DNA |
|---|---|---|
| Founded | 1970 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.4M | 562.3M |
| IPO Year | N/A | N/A |
| Metric | ARKO | DNA |
|---|---|---|
| Price | $4.88 | $9.16 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 3 | 1 |
| Target Price | $7.50 | ★ $9.00 |
| AVG Volume (30 Days) | 479.7K | ★ 1.2M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $7,887,822,000.00 | $180,606,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.28 |
| P/E Ratio | $44.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $5.00 |
| 52 Week High | $7.84 | $17.58 |
| Indicator | ARKO | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.16 | 45.00 |
| Support Level | $4.64 | $8.56 |
| Resistance Level | $4.81 | $9.38 |
| Average True Range (ATR) | 0.17 | 0.55 |
| MACD | 0.05 | 0.26 |
| Stochastic Oscillator | 85.03 | 69.31 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.